1156 related articles for article (PubMed ID: 19323590)
21. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.
Brogan AJ; Mrus J; Hill A; Sawyer AW; Smets E
HIV Clin Trials; 2010; 11(3):133-44. PubMed ID: 20736150
[TBL] [Abstract][Full Text] [Related]
22. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Taiwo B; Murphy RL; Katlama C
Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
[TBL] [Abstract][Full Text] [Related]
23. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
[TBL] [Abstract][Full Text] [Related]
24. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
Venter WDF; Moorhouse M; Sokhela S; Serenata C; Akpomiemie G; Qavi A; Mashabane N; Arulappan N; Sim JW; Sinxadi PZ; Wiesner L; Maharaj E; Wallis C; Boyles T; Ripin D; Stacey S; Chitauri G; Hill A
Lancet HIV; 2019 Jul; 6(7):e428-e437. PubMed ID: 31202690
[TBL] [Abstract][Full Text] [Related]
25. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
26. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
27. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M; Miralles D; Hill A
HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
[TBL] [Abstract][Full Text] [Related]
29. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
[TBL] [Abstract][Full Text] [Related]
30. Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.
Robertson J; Feinberg J
Expert Opin Pharmacother; 2012 Jun; 13(9):1363-75. PubMed ID: 22594781
[TBL] [Abstract][Full Text] [Related]
31. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Lennox JL; Landovitz RJ; Ribaudo HJ; Ofotokun I; Na LH; Godfrey C; Kuritzkes DR; Sagar M; Brown TT; Cohn SE; McComsey GA; Aweeka F; Fichtenbaum CJ; Presti RM; Koletar SL; Haas DW; Patterson KB; Benson CA; Baugh BP; Leavitt RY; Rooney JF; Seekins D; Currier JS;
Ann Intern Med; 2014 Oct; 161(7):461-71. PubMed ID: 25285539
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
34. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Oldfield V; Plosker GL
Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
Poveda E; de Mendoza C; Martin-Carbonero L; Corral A; Briz V; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2007 Oct; 60(4):885-8. PubMed ID: 17646201
[TBL] [Abstract][Full Text] [Related]
36. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
[TBL] [Abstract][Full Text] [Related]
37. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F
Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125
[TBL] [Abstract][Full Text] [Related]
38. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.
Chapman TM; Plosker GL; Perry CM
Drugs; 2004; 64(18):2101-24. PubMed ID: 15341507
[TBL] [Abstract][Full Text] [Related]
39. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
[TBL] [Abstract][Full Text] [Related]
40. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]